Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$12.50 USD
+0.23 (1.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.52 +0.02 (0.16%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum B VGM
Hims & Hers Health, Inc. (HIMS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.40 | $20.00 | $11.00 | 25.51% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Hims & Hers Health, Inc. comes to $15.40. The forecasts range from a low of $11.00 to a high of $20.00. The average price target represents an increase of 25.51% from the last closing price of $12.27.
Analyst Price Targets (13)
Broker Rating
Hims & Hers Health, Inc. currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.92 a month ago based on 12 recommendations.
Of the 13 recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 46.15% and 7.69% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 6 | 6 | 6 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.93 | 2.00 | 1.92 | 1.92 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/26/2024 | Seaport Research Partners | Aaron Kessler | Not Available | Strong Buy |
4/10/2024 | Canaccord Genuity | Maria Ripps | Not Available | Strong Buy |
3/15/2024 | Robert W. Baird & Co. | Vikram Kesavabhotla | Hold | Hold |
2/28/2024 | Imperial Capital | Michael Piccolo | Not Available | Strong Buy |
2/27/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
2/27/2024 | Piper Sandler | Korinne N Wolfmeyer | Hold | Hold |
2/27/2024 | Guggenheim Securities | Jack D Wallace | Strong Buy | Strong Buy |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.93 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 14 |
Average Target Price | $15.94 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | 0.02 |